Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIVE-U Sub-Study A: ARV-471 + Abemaciclib in ER+ Advanced/Metastatic Breast Cancer
NCT05548127Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2023
- Primary completion
- Mar 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 28 days and Objective Response Rate at 1 year. Started Feb 2023; status: active, not recruiting.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05548127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548127.